The NBC broadcast nicely contrasts the demands that glucose monitoring and insulin shots impose on Type I diabetes patients with the tremendous uncertainty associated with experimental stem cell treatments that might free patients from these daily routines. It summarizes the treatment’s apparent benefits and potential harms, as well as ethical concerns about exporting research on dangerous treatments to countries such as Brazil where patients may not fully understand the risks. If the broadcast has a weakness, it is that it fails to mention the limitations inherent in any small, nonrandomized, nonblinded study with short follow-up that investigates a new treatment in patients with a chronic disease requiring lifelong care. (See “Evidence” above.) Even if the treatments were relatively safe and conducted in the U.S., viewers should understand that such studies are awash in potential biases and should always be approached with caution.
There was no discussion of the cost of this experimental procedure, and although it is an experimental procedure, some attempt could have been made to project costs.
The broadcast states that 14 of 15 patients “seem to be cured because they have not needed insulin shots for as long as three years.” This is the main finding of the research and a reasonable summary of the therapy’s benefit.
The broadcast outlines the harms that this “potentially very dangerous procedure” might cause (e.g. infection) as a result of knocking out a patient’s immune system.
The broadcast explains that 14 of the 15 patients who received the experimental treatment no longer need injections of insulin to control their diabetes. Though the broadcast cites experts urging caution about the safety of the new therapy, no one points out that even if the procedure were safe, the remarkable findings could be the result of chance or bias. As the researchers point out in their published manuscript, these findings will need to be validated in studies that randomly assign patients to both the new treatment and a comparison therapy (such as standard care or a sham), assess their health using clinicians who do not know which treatment each patient received, and conduct tests to explain how exactly the new treatment seems to work. Because there is often a period of remission after the onset of Type I diabetes in which patients appear to improve without extraordinary measures, doctors will also have to follow both groups of patients for a longer period of time. The broadcast, though cautious (and limited by TV’s self-imposed time constraints), does not explain this.
The broadcast balances statements from a cautious but hopeful coauthor of the new research with those of both a concerned academic ethicist and the mother of a young girl who has Type I diabetes.
The broadcast transcript mentions insulin injections, the standard of care for Type I diabetes. In addition, the video shows a seven-year-old girl managing her disease through a daily routine of glucose monitoring and insulin shots–an effective way to illustrate the discipline and hardships the current standard therapy imposes on children with the disease, as well as why new approaches would be so welcome.
The story makes it clear that this is an experimental treatment and not widely available.
The broadcast suggests that this form of stem cell therapy is new. This is true, though experimentation with similar treatments for Type I diabetes go back to the 1990s.
No obvious use of text from the press release.
Systematic, Criteria-Driven
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Our editorial team was blessed to have Sharon as a contributor during our best years. As this obit states, she was “kind, patient, wise, thoughtful and generous.” Thank you, Sharon; now rest in peace. https://journalism.wisc.edu/news/in-memoriam-sharon-dunwoody-1947-2022/
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like